Omalizumab effectiveness in patients with a previously failed oral immunotherapy for severe milk allergy

Autor: Irene Berti, Sarah Contorno, Egidio Barbi, Beatrice Belluzzi, Elisa Benelli, Laura Badina, Benedetta Bossini
Přispěvatelé: Badina, Laura, Belluzzi, Beatrice, Contorno, Sarah, Bossini, Benedetta, Benelli, Elisa, Barbi, Egidio, Berti, Irene
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Allergy
Abdominal pain
IgE-mediated food allergie
Administration
Oral
Milk allergy
Omalizumab
IgE-mediated reactions
Desensitization
avoidance diet
Quality of life
Short Reports
Immunologic
Immunology and Allergy
Medicine
Prospective Studies
Oral food challenge
oral immunotherapy
OIT failure
IgE‐mediated food allergies
Milk
IgE-mediated food allergies
anaphylaxis
asthma
omalizumab
severe milk allergy
Animals
Cattle
Desensitization
Immunologic
Female
Humans
Quality of Life
Milk Hypersensitivity
Administration
medicine.symptom
Anaphylaxis
Human
medicine.drug
Oral
medicine.medical_specialty
Immunology
IgE‐mediated reactions
Short Report
anaphylaxi
Internal medicine
Asthma
Animal
business.industry
RC581-607
IgE-mediated reaction
medicine.disease
Prospective Studie
Immunologic diseases. Allergy
business
Zdroj: Immunity, Inflammation and Disease
Immunity, Inflammation and Disease, Vol 10, Iss 1, Pp 117-120 (2022)
ISSN: 2050-4527
Popis: Background Some studies addressed the issue of omalizumab (OML) effectiveness in children starting their first oral immunotherapy (OIT) attempt but no study investigated the possible role of OML in the setting of patients with persisting milk allergy after a failed OIT attempt. Methods Single‐center, prospective, observational study in a selected group of patients with a persisting and severe cow milk (CM) allergy associated with moderate allergic asthma, in which a previous OIT attempt had already failed. We performed an open oral food challenge (OFC) to identify patients who tolerated less than 173 mg of cow's milk protein. At the end of the recruitment, we have found four patients with a mean age of 16.25 years (8–24) who had suspended a previous OIT attempt and still reacted to an amount of CM equal or below 173 mg. Enrolled patients, after an 8‐week course of OML along with a CM avoiding diet, underwent again an open OFC with CM to re‐evaluate their threshold. Eventually, a new OIT course was started using the same OIT protocol of the previous attempt, maintaining cotreatment with OML for the first 12 months. For each patient, we documented: the threshold of CM at OFC, level of specific immunoglobulin E (IgE) and IgG4 for milk, and quality of life (QoL). Results During OIT the four patients experienced no reactions or extremely mild ones (oral itching, transient mild abdominal pain). All increased their threshold of CM in OML if compared with the baseline and maintained it long after that biologic therapy had discontinued. Specific milk proteins IgG4 levels significantly increased in all. Conclusion In this series, OML was effective in patients with severe CM allergy who had previously failed OIT, allowing milk intake without adverse reactions and improving the QoL.
Databáze: OpenAIRE
Externí odkaz: